Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of “Buy” from Analysts

Shares of Nektar Therapeutics (NASDAQ:NKTR) have earned a consensus recommendation of “Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $71.56.

Several analysts have recently commented on the company. ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. William Blair restated a “buy” rating on shares of Nektar Therapeutics in a report on Friday, June 14th. Zacks Investment Research cut Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Cowen set a $200.00 target price on Lululemon Athletica and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, BidaskClub upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 20th.

In other news, SVP Stephen K. Doberstein sold 3,461 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $108,571.57. Following the completion of the transaction, the senior vice president now directly owns 95,913 shares in the company, valued at approximately $3,008,790.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $34.57, for a total value of $864,250.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 219,949 shares of company stock valued at $7,285,900. Corporate insiders own 4.02% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of NKTR. Meeder Asset Management Inc. boosted its stake in shares of Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 479 shares during the period. Quantamental Technologies LLC bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $27,000. CSat Investment Advisory L.P. boosted its stake in shares of Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 790 shares during the period. Enterprise Financial Services Corp bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $67,000. Finally, Belpointe Asset Management LLC bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $100,000. Institutional investors own 92.23% of the company’s stock.

Shares of NKTR stock traded up $0.19 during trading hours on Friday, hitting $33.72. 991,644 shares of the company’s stock were exchanged, compared to its average volume of 1,285,380. The company has a 50-day moving average price of $34.03. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. The firm has a market cap of $5.84 billion, a PE ratio of 8.92 and a beta of 2.74. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $69.76.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analysts’ expectations of $25.45 million. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. During the same quarter in the prior year, the business earned ($0.60) earnings per share. As a group, research analysts expect that Nektar Therapeutics will post -3.14 earnings per share for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: How to Use a Moving Average for Trading 

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.